We are currently developing innovative anticancer companion diagnostics based on the novel mode of action by utilizing the established platform technologies.
Based on the advice of technical and clinical experts, we aimed to obtain ‘Accelerated Approval’ in targeting rare or incurable cancer through the Fast Track as an Orphan Drug designation (ODD) / Breakthrough Therapy designation (BTD) and further develop global anticancer drugs by undertaking continuous research.
We expect to generate immediate profits through accelerated approval of anticancer drugs targeting rare or incurable cancers, and to generate high long-term profits through global anticancer drug development.